ABSTRACT
Background Bullying and the use of psychoactive substances are prevalent conditions among adolescents that appear to have some connection. However, there is no consensus in the literature regarding the association between being a victim of bullying and using psychoactive substances. Moreover, most analyses of this correlation have taken place in developed countries, possibly not reflecting the reality in Latin America.
Objective This cross-sectional study investigated the association between the use of psychoactive substances and involvement in bullying situations in a representative sample of Brazilian adolescents.
Methods We used data from the 2019 National School Health Survey (Pesquisa Nacional de Saúde do Escolar), analyzing 123,261 questionnaires from youths aged 13 to 17. Questions about experiencing or engaging in bullying, lifetime use, and recent use (in the last 30 days) of tobacco, hookah, e-cigarettes, other tobacco products, alcohol, and illicit drugs were considered. Responses on the recent use (in the last 30 days) of the following substances were also analyzed: clove cigarettes, straw cigarettes, marijuana, and crack. Multivariate logistic regression models were used to determine correlations, and odds ratios (OR) were calculated.
Results Participation in bullying situations, whether as a victim or perpetrator, increases the likelihood of using tobacco cigarette, hookah, e-cigarettes, clove cigarettes, straw cigarettes, alcohol, illicit drugs, marijuana, and crack. The non-involved-in-bullying group has a lower chance of using any analyzed substance, followed by the group that is only a victim. Those with the highest likelihood of use are individuals who engage in bullying exclusively, followed by those who experience both situations.
Conclusion In Brazil, being a victim of bullying is associated with the use of various psychoactive substances. Our results align with findings from Latin America, partially differing from studies in developed countries, highlighting the influence of location in understanding these risk associations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally located at: https://www.ibge.gov.br/estatisticas/downloads-estatisticas.html?caminho=pense/2019/microdados/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Title modified to make the study proposal clearer
Data Availability
All data produced in the present work are contained in the manuscript
